This is how I read it.
The key to getting the potency assay validated is a successful randomized controlled clinical trial in adults with biomarker evidence that correlates with the Mechanism of Action and the potency assay. Investors here don't seem to have grasped the concept that that is how the FDA will agree the potency assay has been properly "validated" instead of "improved".
SI is still resisting the idea of doing a randomized and properly controlled clinical trial probably because he's afraid it could fail to show efficay which would completely doom Remestemcel and the company. So he has once again proposed a single arm trial that he thinks stacks the odds more favourably and the FDA have given a luke warm response that they will "consider it" at another meeting. But clearly it's not what they want. What they want to see is the whole box and dice sorted out in one properly designed and executed trial.
- Forums
- ASX - By Stock
- Ann: Mesoblast Type A Meeting with FDA
This is how I read it. The key to getting the potency assay...
-
- There are more pages in this discussion • 541 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 69437 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 19999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1099 | 1.140 |
2 | 12160 | 1.135 |
8 | 5881 | 1.120 |
8 | 32907 | 1.115 |
5 | 122068 | 1.085 |
Price($) | Vol. | No. |
---|---|---|
1.055 | 1538 | 2 |
1.080 | 48 | 1 |
1.085 | 9174 | 1 |
1.090 | 13973 | 2 |
1.095 | 20000 | 1 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online